Kanagawa Children's Medical Center
診療所付近
神奈川県立こども医療センター
医療法人社団ウイズワン ばんば整形外科
港南区芹が谷2-8-11 芹が谷クリニックビル2階
港南区芹が谷2-8-11 芹が谷クリニックビル2階
横浜弘明寺呼吸器内科・内科クリニック
南区六ツ川 1-81 Fhcビル2F
南区六ツ川 1-81 Fhcビル2F
スマイルこどもクリニック東戸塚院
戸塚区品濃町556-8
戸塚区品濃町556-8
医療法人FLATS ヒルサイドクリニック
横浜市港南区上大岡西
横浜市港南区上大岡西
育生会横浜病院
保土ケ谷区狩場町
保土ケ谷区狩場町
歯科さめじま Holistic Dental Care
戸塚区品濃町
戸塚区品濃町
いなばクリニック inaba clinic
横浜市港南区港南中央通13-24
横浜市港南区港南中央通13-24
日野病院
横浜市港南区日野3-9-3
横浜市港南区日野3-9-3
ともともクリニック
横浜市南区大岡
横浜市南区大岡
汐見台病院
235-0022
235-0022
【横浜保土ヶ谷の整体】ふじたカイロプラクティック
保土ヶ谷区月見台36−3 メゾンフクダ102
保土ヶ谷区月見台36−3 メゾンフクダ102
とつか西口整形外科スポーツ医学センター
戸塚区戸塚町
戸塚区戸塚町
新緑脳神経外科/横浜サイバーナイフセンター
旭区市沢町
旭区市沢町
矢吹整形外科
磯子区丸山2丁目3-6
磯子区丸山2丁目3-6
健康・美容事業付近
横浜市永田地域ケアプラザ
南区永田南2-16-31
南区永田南2-16-31
ひらの接骨院
弘明寺町
弘明寺町
アレッタ児童デイサービス弘明寺
南区大橋町 3‐64‐5 弘明寺シティーホーム
南区大橋町 3‐64‐5 弘明寺シティーホーム
横浜市港南区健康経営はじめの一歩
横浜市港南区港南
横浜市港南区港南
アレッタ児童デイサービス阪東橋
2320012
2320012
社労士/行政書士/afpの話題
神奈川県横浜市戸塚区上倉田町884-1戸塚ハイライズ628号
神奈川県横浜市戸塚区上倉田町884-1戸塚ハイライズ628号
ジム/スポーツ施設付近
イトマンスイミングスクール
永田台 6-19, 南区
永田台 6-19, 南区
平和台ブルーツインズ【横浜市戸塚区 少年野球チーム】
Isao Yoneda Gymnastics & Swimming
港南区下永谷 6-1-1 Isao Yoneda Academy
港南区下永谷 6-1-1 Isao Yoneda Academy
ひらの接骨院
弘明寺町
弘明寺町
井土ケ谷フレンズ / 横浜市南区・少年少女野球チーム
2320007
2320007
Anuanua Dance School by FENUA Fitness
2320006
2320006
コメント
We are excited to announce Samuel's publication, Functional Genomic Analysis of Epithelioid Sarcoma Reveals Distinct Proximal and Distal Subtype Biology is now published in the journal, Clinical and Translational Medicine. You can read the article here: https://doi.org/10.1002/ctm2.961
In this study, an international group of collaborators defined the genetic landscape of the largest group of epithelioid sarcoma (EPS) patients thus far. A difference was seen between the mutation types and genes turned on between the 2 subtypes of EPS.
Funding partner Becky Hughes, President of Prayers for Elijah, expresses the resounding sentiments of childhood cancer families, “While we are so extremely grateful to cc-TDI and the insurmountable time and efforts they are putting towards EPS research, it’s evident there’s so much more to uncover about this unconventional and highly destructive cancer that took the life of not only Elijah at 10 years old, but so many other children. We do not want any other child to have to suffer as Elijah did or hear those terrifying words, ‘there are no treatment options for you.’ We will continue to implore other medical institutions to join in our fight against childhood cancer with emphasis on rare cancers like EPS.”
Beth Barnes Norton, Corry's Mom illustrates the pain clearly. "This disease reaches children and adults of all ages. My son was 29 years old when he was diagnosed. He was married with a 2 year-old son and a 2 month-old daughter. He took every treatment, surgery, homeopathic treatment, and trial drugs to no avail. The impact of this awful cancer on patients and families is relentless and the treatments are brutal and ancient."
Kim Webb, Connor's Mom, describes the ongoing challenge of EPS. "EPS is an exceptionally rare and deadly disease with a high recurrence rate. Beyond surgery, there are few options for treatment and even then, the most brutal medications do not stop this beast. The only chance we have is through collaborative research. We need a united front of researchers, clinicians, pharma, families and funding all working together simultaneously. It is the only way and our only hope."
Co-authors are cc-TDI Team members and alumni Lissett, Andy, Ken, and Noah. International collaborators included Thomas G. P. Grünewald, Felix Sahm and Jia xiang Jin at the German Cancer Consortium in Heidelberg; Hiroaki Goto at the Kanagawa Children's Medical Center in Yokohama, Japan; Angelo Sidoni at MD Anderson Cancer Center in Houston; Erin Rudzinski at Seattle Children's; Khin Thway and Robin L. Jones at The Royal Marsden Hospital in London, UK; Paul H. Huang at the The Institute of Cancer Research in London; Alessio Ciulli at the University of Dundee, Scotland; and the talented team of Hollis Wright, Melvin Lathara, Ganapati Srinivasa and Kavya Kannan at Omics Data Automation in Oregon.
This work was supported by the Sam Day Foundation, direct contributions from EPS families and contributions made from private donors through Consano.org. This manuscript was written in honor of Connor Webb, Cory Norton, Jaya Gupta, Ella Engeström and Elijah Hughes. We are grateful to Drs. William Tap, Robert Maki, Lia Gore, Carrye Cost, Margaret Macy and Robin Jones for assistance with therapeutic agent selection. We thank Dr. Torsten Nielsen for early discussions of this project. The laboratory of T.G.P.G. was supported by the SMARCB1 association and the Barbara and Wilfried Mohr Foundation.
The exciting next step for this international consortium, which will include Dr Sophie Postel-Vinay at Hopital Institute Gustave Roussy in France, will be to define the mechanism of action of FDA-approved tazemetostat and how new drugs can be combined with tazemetostat to improve treatment outcomes.
In this study, an international group of collaborators defined the genetic landscape of the largest group of epithelioid sarcoma (EPS) patients thus far. A difference was seen between the mutation types and genes turned on between the 2 subtypes of EPS.
Funding partner Becky Hughes, President of Prayers for Elijah, expresses the resounding sentiments of childhood cancer families, “While we are so extremely grateful to cc-TDI and the insurmountable time and efforts they are putting towards EPS research, it’s evident there’s so much more to uncover about this unconventional and highly destructive cancer that took the life of not only Elijah at 10 years old, but so many other children. We do not want any other child to have to suffer as Elijah did or hear those terrifying words, ‘there are no treatment options for you.’ We will continue to implore other medical institutions to join in our fight against childhood cancer with emphasis on rare cancers like EPS.”
Beth Barnes Norton, Corry's Mom illustrates the pain clearly. "This disease reaches children and adults of all ages. My son was 29 years old when he was diagnosed. He was married with a 2 year-old son and a 2 month-old daughter. He took every treatment, surgery, homeopathic treatment, and trial drugs to no avail. The impact of this awful cancer on patients and families is relentless and the treatments are brutal and ancient."
Kim Webb, Connor's Mom, describes the ongoing challenge of EPS. "EPS is an exceptionally rare and deadly disease with a high recurrence rate. Beyond surgery, there are few options for treatment and even then, the most brutal medications do not stop this beast. The only chance we have is through collaborative research. We need a united front of researchers, clinicians, pharma, families and funding all working together simultaneously. It is the only way and our only hope."
Co-authors are cc-TDI Team members and alumni Lissett, Andy, Ken, and Noah. International collaborators included Thomas G. P. Grünewald, Felix Sahm and Jia xiang Jin at the German Cancer Consortium in Heidelberg; Hiroaki Goto at the Kanagawa Children's Medical Center in Yokohama, Japan; Angelo Sidoni at MD Anderson Cancer Center in Houston; Erin Rudzinski at Seattle Children's; Khin Thway and Robin L. Jones at The Royal Marsden Hospital in London, UK; Paul H. Huang at the The Institute of Cancer Research in London; Alessio Ciulli at the University of Dundee, Scotland; and the talented team of Hollis Wright, Melvin Lathara, Ganapati Srinivasa and Kavya Kannan at Omics Data Automation in Oregon.
This work was supported by the Sam Day Foundation, direct contributions from EPS families and contributions made from private donors through Consano.org. This manuscript was written in honor of Connor Webb, Cory Norton, Jaya Gupta, Ella Engeström and Elijah Hughes. We are grateful to Drs. William Tap, Robert Maki, Lia Gore, Carrye Cost, Margaret Macy and Robin Jones for assistance with therapeutic agent selection. We thank Dr. Torsten Nielsen for early discussions of this project. The laboratory of T.G.P.G. was supported by the SMARCB1 association and the Barbara and Wilfried Mohr Foundation.
The exciting next step for this international consortium, which will include Dr Sophie Postel-Vinay at Hopital Institute Gustave Roussy in France, will be to define the mechanism of action of FDA-approved tazemetostat and how new drugs can be combined with tazemetostat to improve treatment outcomes.
The Kanagawa Children's Medical Center is a children's hospital in Yokohama, Japan. The center is a core facility of pediatric care for Kanagawa Prefecture.
It consists of a research institute and hospital, and is now an ancillary establishment of Kanagawa Prefectural Hospital Organization.HistoryThe Kanagawa Children's Medical Center was established in 1970 as the first children's hospital in Kanagawa Prefecture.OrganizationHospitalClinical Research Institute
カテゴリー
住所
Yokohama, Kanagawa
病院のその他Yokohama (すべて表示)
港北区北新横浜1-6-2
Yokohama, 223-0059
ゆうあいクリニックは「がん」をはじめとする生活習慣病の早期発見を目的として2004年に誕生しました。「検査に特化したクリニック」として、健康な人を対象とした人間ドックのほ